Sort   by:  
 Page size 
UnknownAssessing the impact of revising MenACWY vaccination schedule for adolescents in the United States: a modelling study.

Background

The current recommendation for MenACWY vaccination against invasive meningococcal disease (IMD) in the United States (US) includes two doses: the first dose at ages 11-12 and a booster dose at age 16. The Advisory Committee on Immunization Practices has proposed options for revisi...
S-EPMC11880592 | biostudies-literature
UnknownCost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study.

Background

The cost-effectiveness of immunisation strategies with a long-acting monoclonal antibody (nirsevimab) and/or a protein-based maternal vaccine (RSVpreF) for protecting infants from Respiratory Syncytial Virus (RSV)-associated illness has not been previously determined for Canada. W...
S-EPMC10663690 | biostudies-literature
Sort   by:  
 Page size